Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/01/18 16:16:22」(JST)

wiki en

Clenoliximab (INN^[1]) is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis.^[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.^[1]

References[edit]

^ ^a ^b World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77". WHO Drug Information 11 (2): 89.
^ Hepburn, TW; Totoritis, MC; Davis, CB (2003). "Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.". Rheumatology (Oxford, England) 42 (1): 54–61. doi:10.1093/rheumatology/keg030. PMID 12509613.

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

English Journal

Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.

Ternant D, Paintaud G.SourceFrançois-Rabelais University, UPRES EA 3853 Immuno-Pharmaco-Genetics of Therapeutic Antibodies, Faculty of Medicine, F 37032 Tours Cedex 1, France.
Expert opinion on biological therapy.Expert Opin Biol Ther.2005 Sep;5 Suppl 1:S37-47.
Although monoclonal antibodies (mAbs) constitute a major advance in therapeutics, their pharmacokinetic (PK) and pharmacodynamic (PD) properties are not fully understood. Saturable mechanisms are thought to occur in distribution and elimination of mAbs, which are protected from degradation by the Br
PMID 16187939

Gateways to clinical trials.

Bayés M, Rabasseda X, Prous JR.SourceProus Science, Barcelona, Spain. mbayes@prous.com
Methods and findings in experimental and clinical pharmacology.Methods Find Exp Clin Pharmacol.2003 Sep;25(7):565-97.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.c
PMID 14571286

Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.

Hepburn TW, Totoritis MC, Davis CB.SourceDrug Metabolism and Pharmacokinetics, GlaxoSmithKline, 709 Swedeland Road, PO Box 1539 (UW2720), King of Prussia, PA 19406, USA. timothy_w_hepburn@gsk.com
Rheumatology (Oxford, England).Rheumatology (Oxford).2003 Jan;42(1):54-61.
OBJECTIVE: Keliximab studies have provided evidence of the therapeutic potential of a non-depleting CD4 monoclonal antibody (mAb) in the treatment of rheumatoid arthritis (RA). Clenoliximab, an immunoglobulin G4 derivative of keliximab, has substantially reduced potential to deplete CD4 cells. In in
PMID 12509613

Related Pictures

★リンクテーブル★

リンク元

「mab」

Clenoliximab ^?
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (primate/human)
Target	CD4
Clinical data
Legal status	?
Identifiers
ATC code	None
Chemical data
Formula	?
(what is this?) (verify)